NCT01526486

Brief Summary

Patients with melanoma, some other rare skin cancers, and some cancers of the penis and scrotum can have their cancer spread to the lymph nodes in the upper part of the leg, called the groin. Medically, this area is called the inguinal area. At present, for melanomas and skin cancers this type of spread is usually found with a special test called a "sentinel lymph node biopsy". This procedure can find spread of even a few cells in a single lymph node-allowing the treating doctor to find the spread very early. Treatment for patients with skin cancer in the lymph nodes in this area is to remove all of the lymph nodes in this area. In patients with cancers of the penis and scrotum who do hot have any evidence of cancer having spread either by physical examination or by radiology tests, the lymph nodes in this area are removed to check and see if there is cancer in them. This is called staging. At present, the standard way to remove all of the lymph nodes in the groin is by a large incision, approximately 8-10 inches in length. For patients who have this operation, there is a very high incidence of infection after surgery: as many as 50% as patients can have a problem after surgery. These infections range from a low grade skin infection needing oral antibiotics to deep infections requiring the wound to be opened and occasionally needing readmission to the hospital and antibiotics given via the vein. With the advent of new technology and new equipment, the ability to perform this procedure through small incisions away from the groin and further down the leg has become possible. This procedure has never been performed routinely nor compared side by side to the standard open approach. The investigators propose to perform this protocol in two phases. The investigators have performed procedures in 20 groins to this point and have confirmed the number of lymph nodes and visually verified that the procedure is identical to the open procedure. The investigators performed these procedures in order to insure that the investigators were offering an equivalent option regardless of which procedure the patient is randomized to. The study will involve the randomization of patients undergoing the procedure. The investigators will randomize the next 110 patients in a 2:1 fashion (two people will get the videoscopic procedure for every one who gets the open procedure) until 73 patients are included in the video arm and 37 in the open arm. Outcomes including recurrence rate, duration of drain requirements, and incidence of lymphedema will be followed. Patients will be followed using standard of care processes, including regular office visits, physical exams, and radiographic imaging, when indicated. Patients will be followed for 5 years.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2009

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2009

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

January 28, 2012

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 6, 2012

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2013

Completed
Last Updated

May 6, 2015

Status Verified

May 1, 2015

Enrollment Period

3.7 years

First QC Date

January 28, 2012

Last Update Submit

May 4, 2015

Conditions

Keywords

melanomaurologyinguinallymph nodesgroinlymphadenectomygroin dissectionskin cancerpenile cancerurethral cancerscrotal cancerPaget's disease

Outcome Measures

Primary Outcomes (4)

  • Complication profile

    The primary objective is to assess wound infection, wound dehiscence and other wound complications.

    30 days

  • Length of stay

    Hospital length of stay.

    1- 7 days

  • Lymphedema

    Assessment of lymphedema will be determined in all patients to identify if there is a difference in all patients undergoing either videoscopic or open inguinal lymphadenectomy.

    5 years

  • Nodal yield

    This will characterize, as a surrogate of completeness of surgery, the number of nodes retrieved at the surgical procedure via either approach.

    5-7 days post procedure

Secondary Outcomes (2)

  • Readmission

    30 days

  • Oncologic outcomes--survival

    5 years

Study Arms (2)

Videoscopic (Minimally invasive)

EXPERIMENTAL

Patients in this arm will have the procedure done through the three port minimally invasive approach.

Procedure: Videoscopic procedure

Open (traditional approach)

ACTIVE COMPARATOR

Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.

Procedure: Open, traditional approach

Interventions

Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).

Videoscopic (Minimally invasive)

Open surgical procedure, with sartorius muscle transfer.

Open (traditional approach)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients will be considered for this study if they are between age 18 and 80
  • Patients have either metastatic melanoma or merkel cell carcinoma diagnosed by sentinel lymph node biopsy or are candidates for a staging procedure for either a penile or scrotal carcinoma

You may not qualify if:

  • Patients with unresectable metastatic disease
  • Patients who are pregnant or lactating
  • Patients with prohibitive cardiac or pulmonary comorbidities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emory University Hospital-Winship Cancer Institute

Atlanta, Georgia, 30322, United States

Location

Related Publications (4)

  • Delman KA, Kooby DA, Rizzo M, Ogan K, Master V. Initial experience with videoscopic inguinal lymphadenectomy. Ann Surg Oncol. 2011 Apr;18(4):977-82. doi: 10.1245/s10434-010-1490-5. Epub 2010 Dec 24.

    PMID: 21184190BACKGROUND
  • Delman KA, Kooby DA, Ogan K, Hsiao W, Master V. Feasibility of a novel approach to inguinal lymphadenectomy: minimally invasive groin dissection for melanoma. Ann Surg Oncol. 2010 Mar;17(3):731-7. doi: 10.1245/s10434-009-0816-7.

    PMID: 20183910BACKGROUND
  • Master V, Ogan K, Kooby D, Hsiao W, Delman K. Leg endoscopic groin lymphadenectomy (LEG procedure): step-by-step approach to a straightforward technique. Eur Urol. 2009 Nov;56(5):821-8. doi: 10.1016/j.eururo.2009.07.003. Epub 2009 Jul 15.

    PMID: 19640633BACKGROUND
  • Tobias-Machado M, Tavares A, Molina WR Jr, Zambon JP, Medina JA, Forseto PH Jr, Juliano RV, Wroclawski ER. Video endoscopic inguinal lymphadenectomy (VEIL): initial case report and comparison with open radical procedure. Arch Esp Urol. 2006 Oct;59(8):849-52. doi: 10.4321/s0004-06142006000800020.

    PMID: 17153511BACKGROUND

Related Links

MeSH Terms

Conditions

MelanomaCarcinoma, Merkel CellCarcinoma, Squamous CellPenile NeoplasmsUrethral NeoplasmsPaget Disease, ExtramammaryAnus NeoplasmsVulvar NeoplasmsSkin NeoplasmsLymphadenopathyOsteitis Deformans

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasNeoplasms by SiteSkin DiseasesSkin and Connective Tissue DiseasesPolyomavirus InfectionsDNA Virus InfectionsVirus DiseasesInfectionsTumor Virus InfectionsCarcinoma, NeuroendocrineAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms, Squamous CellGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesPenile DiseasesMale Urogenital DiseasesUrologic NeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrethral DiseasesUrologic DiseasesNeoplasms, Ductal, Lobular, and MedullaryRectal NeoplasmsColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesAnus DiseasesRectal DiseasesGenital Neoplasms, FemaleVulvar DiseasesGenital Diseases, FemaleLymphatic DiseasesHemic and Lymphatic DiseasesBone DiseasesMusculoskeletal Diseases

Study Officials

  • Keith Delman, MD

    Emory University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Surgery

Study Record Dates

First Submitted

January 28, 2012

First Posted

February 6, 2012

Study Start

June 1, 2009

Primary Completion

February 1, 2013

Study Completion

February 1, 2013

Last Updated

May 6, 2015

Record last verified: 2015-05

Locations